Trioxifene

Trioxifene (INN; developmental code LY-133,314), or as the salt trioxifene mesylate (USAN), is a selective estrogen receptor modulator (SERM) with competitive binding activity against estradiol for the ERα and antagonistic activity against ERα-mediated gene expression, that was under preclinical and clinical development by Eli Lilly and Company for breast cancer and prostate cancer,^[1] but was abandoned.^{[2]: 11 [3][4]} Its affinity for the rat estrogen receptor was reported to be 20% relative to estradiol.^[5][6]

Trioxifene

Clinical data
Other names	LY-133,314
Routes of administration	Oral
ATC code	none
Identifiers
IUPAC name [2-(4-methoxyphenyl)-3,4-dihydronaphthalen-1-yl]-[4-(2-pyrrolidin-1-ylethoxy)phenyl]methanone
CAS Number	63619-84-1 68307-81-3 (mesylate)
PubChem CID	50139
ChemSpider	45471
UNII	R0130F043H
CompTox Dashboard (EPA)	DTXSID30212997
Chemical and physical data
Formula	C30H31NO3
Molar mass	453.582 g·mol−1